An independent newsroom of one. Every story is cross-referenced across multiple trusted Indian publications, scored, and rewritten without ads, bias, or noise.

News

Politics
Business
Sports
Technology
World
Entertainment

About

How verification works
Saved stories

Legal

Privacy Policy
Terms of Use
Corrections Policy
Contact & Tips

Transparency

No advertising or sponsored content
Every claim links back to its sources
Open-source under the MIT licence
AI cross-verifies before publishing

Built in IndiaDesigned & engineered by Roshhellwett, with the help of Claude & other tools.

Home

Swipe

Saved

Junshi Biosciences Announces Toripalimab NDA Approval — India Verified

Back to all news

Health
Junshi Biosciences Announces Toripalimab NDA Approval

Health22 May 2026 at 04:28 pmQuick read

Junshi Biosciences Announces Toripalimab NDA Approval

Credibility score90 / 100

LowModerateHigh

2sources verified

Junshi Biosciences announced the approval of Toripalimab NDA. The NDA was approved for the 1st-line treatment of HER2 expressing urothelial carcinoma. The approval was granted by the NMPA.

AI Credibility Analysis

The score is 90 because it falls within the 90-100 band, with 2+ authoritative named sources, including GlobeNewswire, providing specific data and official statements about the approval of Toripalimab's NDA.

Original Sources

Financialpost
Globenewswire

How this story was built

Cross-Referenced

2 Sources

Unbiased AI

⚡

Auto-Published

Junshi Biosciences Announces Toripalimab NDA Approval

How this story was built

Related stories

West Bengal to revamp healthcare with Ayushman Bharat

Telangana heatwave claims 16 lives

Delhi Experiences Relief From Heatwave